stockrow
Friday 6 November 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024.
- Revenue
- +7.54%
- EPS
- −128.6%
- Free cash flow
- +2,058.7%
Quarter to September 2026, against a year earlier
22.24
3.58
+19.19%
Follow FLGT
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 5.97 | 5.81 | 6.48 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 5 | 4 | 6 | 6 | 5 | 5 | 4 | 6 | 4 |
P/S ratio |
8.36 | 4.01 | 2.67 | 7.42 | 2.80 | 2.98 | 1.49 | 3.02 | 1.97 | 2.51 |
Altman Z-Score |
26.24 | 14.85 | 11.69 | 24.02 | 8.36 | 19.45 | 6.78 | 5.91 | 4.68 | 5.63 |
P/FCF ratio |
243.81 | 0.00 | 0.00 | 55.67 | 11.21 | 5.75 | 3.92 | 156.59 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
15.65 | 18.66 | 19.55 | 14.64 | 11.73 | 18.68 | 16.78 | 14.58 | 15.74 | 14.32 |
P/Operating CF |
121.90 | (60.46) | 73.25 | (2,080.57) | 8.81 | 38.37 | 27.79 | 58.42 | 22.32 | (10.35) |
Beneish M-Score |
(0.29) | (2.97) | (2.66) | (1.53) | 8.62 | (1.34) | (3.70) | (2.55) | (1.99) | (2.35) |
P/B ratio |
2.81 | 1.39 | 1.11 | 2.92 | 2.08 | 2.54 | 0.73 | 0.77 | 0.49 | 0.73 |
Price to Tangible BV |
2.81 | 1.39 | 1.11 | 2.92 | 2.08 | 2.74 | 0.95 | 0.90 | 0.54 | 0.80 |
EV/Sales |
7.22 | 2.59 | 1.22 | 6.63 | 2.13 | 2.55 | 0.67 | 1.62 | 1.13 | 1.53 |
EV/EBITDA |
61.37 | 0.00 | 0.00 | 120.87 | 3.06 | 3.64 | 1.93 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
29.97 | 36.48 | (38.45) | 39.11 | 6.39 | 4.70 | 1.65 | 17.37 | 15.26 | (4.85) |
EV/FCF |
210.52 | (12.06) | (7.40) | 49.77 | 8.52 | 4.91 | 1.78 | 84.22 | (16.96) | (3.97) |
Quick Ratio |
7.61 | 10.16 | 13.51 | 9.35 | 3.71 | 5.60 | 6.57 | 6.51 | 4.49 | 4.95 |
Current Ratio |
7.88 | 10.98 | 14.44 | 9.96 | 4.02 | 5.81 | 7.13 | 6.96 | 4.85 | 6.48 |
Net Debt/EBITDA |
(9.70) | 19.14 | 11.89 | (15.84) | (0.97) | (0.63) | (2.37) | 7.99 | 4.73 | 4.66 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 2.14% | 1.18% | 1.08% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.57 | 0.33 | 0.38 | 0.46 | 1.07 | 1.00 | 0.46 | 0.22 | 0.23 | 0.27 |
Operating CF/Net income |
(0.32) | (0.53) | 0.12 | (13.42) | 0.66 | 1.06 | 1.77 | (0.16) | (0.49) | 1.68 |
Capex/Depreciation |
(3.06) | (2.55) | (1.15) | (0.53) | (9.20) | (1.28) | (0.49) | (0.15) | (2.06) | (1.19) |
Interest Coverage |
— | (7.62) | (8.77) | (0.49) | 193.44 | 519.96 | 176.24 | (400.67) | 434.81 | (1,214.61) |
| (45.84%) | (4.62%) | (10.65%) | (0.61%) | 65.72% | 58.48% | 11.77% | (13.97%) | (3.78%) | (5.41%) | |
| (42.79%) | (4.36%) | (10.09%) | (0.58%) | 54.31% | 51.27% | 10.76% | (12.80%) | (3.48%) | (4.97%) | |
ROIC |
1.71% | (7.86%) | (15.75%) | (0.49%) | 63.62% | 57.83% | 14.71% | (17.23%) | (5.30%) | (7.39%) |
Return on Tangible Assets |
(47.03%) | (6.75%) | (12.96%) | (1.05%) | 49.41% | 89.18% | 23.09% | (32.38%) | (11.06%) | (10.47%) |
Average Days of Receivables |
87.16 | 78.05 | 101.68 | 73.55 | 159.13 | 51.08 | 31.11 | 64.53 | 88.87 | 95.88 |
Research and Development Expense of Revenue |
19.47% | 22.55% | 25.92% | 20.10% | 2.75% | 2.44% | 4.67% | 14.33% | 17.22% | 16.71% |
Selling, General and Administrative Expense of Revenue |
38.73% | 50.39% | 47.73% | 37.85% | 7.15% | 7.57% | 24.23% | 45.11% | 43.87% | 49.60% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.21 | 0.13 | 0.08 | 0.07 |
Share Based Compensation of Revenue |
25.47% | 11.31% | 10.79% | 9.87% | 1.93% | 1.60% | 5.27% | 14.84% | 15.69% | 12.27% |
Graham Net Nets |
0.15 | 0.40 | 0.65 | 0.13 | 0.33 | 0.17 | 0.55 | 0.47 | 0.47 | 0.55 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 70.16 | 124.26 | 67.01 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(3.98%) | (3.58%) | (9.89%) | (0.11%) | 16.74% | 17.21% | 15.43% | (19.26%) | (7.63%) | (7.46%) |
Free Cash Flow Yield |
0.41% | (5.36%) | (6.15%) | 1.80% | 8.92% | 17.40% | 25.48% | 0.64% | (3.39%) | (15.36%) |
Revenue per Share |
1.33 | 1.06 | 1.19 | 1.74 | 18.58 | 33.75 | 20.57 | 9.71 | 9.38 | 10.48 |
Operating CF per Share |
0.32 | 0.08 | (0.04) | 0.29 | 6.20 | 18.31 | 8.42 | 0.91 | 0.70 | (3.30) |
Capex per Share |
(0.28) | (0.30) | (0.16) | (0.06) | (1.55) | (0.81) | (0.61) | (0.72) | (1.32) | (0.73) |
Free Cash Flow per Share |
0.05 | (0.23) | (0.20) | 0.23 | 4.65 | 17.51 | 7.81 | 0.19 | (0.63) | (4.04) |
Cash per Share |
1.52 | 1.49 | 1.73 | 1.51 | 13.19 | 15.32 | 17.48 | 14.24 | 8.54 | 10.92 |
Shareholders Equity per Share |
3.97 | 3.05 | 2.85 | 4.42 | 25.09 | 39.65 | 42.19 | 38.05 | 37.35 | 35.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.97 | 3.05 | 2.85 | 4.42 | 25.09 | 39.65 | 42.19 | 38.05 | 37.35 | 35.96 |
Free Cash Flow |
0.63 | (4.02) | (3.51) | 4.34 | 105.51 | 514.80 | 235.16 | 5.57 | (18.94) | (124.21) |
Working Capital |
22.82 | 29.93 | 36.81 | 33.36 | 393.50 | 506.65 | 539.77 | 434.83 | 280.67 | 465.52 |
Capital Expenditures |
(3.78) | (5.36) | (2.83) | (1.18) | (35.12) | (23.78) | (18.36) | (21.43) | (40.00) | (22.57) |
Net Current Asset Value |
22.58 | 29.92 | 36.79 | 31.10 | 392.54 | 499.12 | 511.70 | 405.80 | 262.77 | 443.68 |
EV/EBIT |
143.79 | 0.00 | 0.00 | 0.00 | 3.10 | 3.74 | 2.34 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.21 | 0.29 | 0.13 | 0.04 | 0.08 | 0.02 | 0.03 | 0.07 | 0.14 | 0.07 |
Price to Operating Income |
166.52 | 0.00 | 0.00 | 0.00 | 4.07 | 4.38 | 5.17 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.20 | 0.29 | 0.38 | 0.37 | 0.10 | 0.30 | 0.46 | 1.71 | 0.18 | 0.17 |
Cash ROIC |
0.83% | (4.99%) | (4.27%) | 3.90% | 11.94% | 31.55% | 12.98% | 0.36% | (1.37%) | (8.61%) |
Accounts Receivable Turnover |
5.64 | 4.48 | 4.29 | 5.20 | 4.43 | 6.15 | 6.46 | 5.57 | 4.72 | 4.20 |
Accounts Payable Turnover |
4.38 | 3.53 | 6.29 | 9.75 | 6.40 | 9.18 | 11.57 | 9.61 | 10.45 | 10.36 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
149.65 | 89.17 | 44.80 | 40.91 | 107.65 | 34.71 | 33.44 | 30.34 | 38.03 | 35.50 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
3.24 | 4.18 | 4.98 | 6.25 | 95.21 | 161.38 | 95.83 | 51.94 | 60.08 | 76.89 |
Average Payables |
1.54 | 2.42 | 1.70 | 1.45 | 14.03 | 23.49 | 21.79 | 19.23 | 16.86 | 18.51 |
Average Assets |
31.94 | 57.61 | 55.54 | 71.33 | 394.61 | 989.59 | 1,332.39 | 1,310.69 | 1,227.65 | 1,216.74 |
Average Common Equity |
29.81 | 54.33 | 52.67 | 66.96 | 326.08 | 867.63 | 1,217.88 | 1,201.58 | 1,131.22 | 1,117.94 |
Columns are period end dates · fundamentals updated 5 Nov 2026